Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) Enterprise Value: 2022-2025

Historic Enterprise Value for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to $5.7 billion.

  • Axsome Therapeutics' Enterprise Value rose 43.87% to $5.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.8 billion, marking a year-over-year increase of 63.08%. This contributed to the annual value of $3.8 billion for FY2024, which is 11.98% up from last year.
  • Latest data reveals that Axsome Therapeutics reported Enterprise Value of $5.7 billion as of Q3 2025, which was up 18.58% from $4.8 billion recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Enterprise Value registered a high of $5.7 billion during Q3 2025, and its lowest value of $1.4 billion during Q2 2022.
  • Its 3-year average for Enterprise Value is $3.8 billion, with a median of $3.5 billion in 2024.
  • Data for Axsome Therapeutics' Enterprise Value shows a peak YoY spiked of 90.13% (in 2023) over the last 5 years.
  • Over the past 4 years, Axsome Therapeutics' Enterprise Value (Quarterly) stood at $3.1 billion in 2022, then rose by 7.35% to $3.4 billion in 2023, then rose by 11.98% to $3.8 billion in 2024, then soared by 43.87% to $5.7 billion in 2025.
  • Its last three reported values are $5.7 billion in Q3 2025, $4.8 billion for Q2 2025, and $5.4 billion during Q1 2025.